News
|
Careers
|
Contact Us
About Vanda
Development Pipeline
24
Discovery Research
Investor Relations
meet vanda
We are using pharmacogenetics to match promising molecules
to the right patients. So selecting the right medicine will be
easier, thanks to our more personal approach.
Jan 26, 2012
Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder
Jan 19, 2012
Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012
Dec 13, 2011
Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanaptâ„¢ in Israel
Read More in the Newsroom
Fanapt™(iloperidone)
Tasimelteon